Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 : vimarsana.com

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXI...

Related Keywords

Australia , Sydney , New South Wales , San Diego , California , United States , American , Youtube Imugenelimited , Leslie Chong , Daneng Li , Heather Armstrong , Matt Wright , Imugene Limited , Twitter , American Association For Cancer Research , Linkedin Imugene , Department Of Medical Oncology Therapeutics Research , American Association , Cancer Research , Annual Meeting , Medical Oncology , Therapeutics Research , Presentation Number , Tuesday April , First In Human Phasei Clinical Trials , Dose Escalation Safety , Tolerability Study , Administered Intratumorally , Adult Patients , Advanced Solid , Chief Executive ,